Genus  (LON:GNS)

Genus (LON:GNS)


Share Price
2,620.00 p
Change
20 (0.77 %)
Market Cap
£1,704.43 m
Proactive Investors - Run By Investors For Investors

Genus RNS Release

Director Declaration


RNS Number : 9084H
Genus PLC
21 November 2018
 

21 November 2018

Genus plc

Director Declaration

Genus plc (LSE: GNS) today announces that Lykele van der Broek, Non-Executive Director, has been appointed as a Non-Executive Director and Chairman of the Supervisory Board of Aspen Oss B.V., a manufacturer of active pharmaceutical ingredients in the human healthcare sector, which is a wholly owned subsidiary of Aspen Pharmacare Holdings Ltd listed on the Johannesburg Stock Exchange, with effect from 21 November 2018.

This announcement is being made pursuant to 9.6.14 of the Listing Rules.

 

For further information please contact:

Genus:

Dan Hartley, Group General Counsel & Company Secretary                         Tel: +44 (0)1256 347100

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RDNBBLFLVFFEFBX

Genus Timeline

Newswire
February 16 2015

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use